CCO Management Series

The Role of Integrase Inhibitors in HIV Management

Targeting Integrase: Mechanisms of Action and Mechanisms of Resistance to Integrase Inhibitors

Module 1 of 3

Faculty:
Martin Markowitz, MD

CME CREDIT INFORMATION

Release Date: 05/15/08

Expiration Date: 05/14/09

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.0 Nursing CE credit

Status: Please log in to view status

Martin Markowitz, MD, discusses the role of the integrase enzyme in the HIV replication cycle and the development of resistance to integrase inhibitors.

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the role of the integrase enzyme in the HIV replication cycle
Discuss the mechanism of action of the current integrase strand transfer inhibitors raltegravir and elvitegravir
Summarize the findings regarding the development of resistance in clinical trials of elvitegravir and raltegravir
Discuss issues relating to cross-resistance between the integrase inhibitors elvitegravir and raltegravir

Clinical Studies of Integrase Inhibitors: A Comprehensive Review

Module 2 of 3

Faculty:
Martin Markowitz, MD

CME CREDIT INFORMATION

Release Date: 04/22/08

Expiration Date: 04/21/09

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.0 Nursing CE credit

Status: Please log in to view status

Martin Markowitz, MD, discusses recent data from clinical studies involving the use of the integrase inhibitors raltegravir and elvitegravir.

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize the results of proof-of-concept clinical trials concerning the use of the integrase inhibitors raltegravir and elvitegravir as monotherapy
Describe the results of clinical trials involving the use of raltegravir and elvitegravir in combination therapy regimens in treatment-naive and treatment-experienced patients
Discuss the role of additional active agents in the optimized background regimens of raltegravir- and elvitegravir-containing antiretroviral therapy regimens

From Bench to Bedside: The Clinical Role of Integrase Inhibitors

Module 3 of 3

Faculty:
David A. Cooper, MD, DSc

CME CREDIT INFORMATION

Release Date: 05/15/08

Expiration Date: 05/14/09

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.0 Nursing CE credit

Status: Please log in to view status

David A. Cooper, MD, DSc, discusses clinical data on the use of integrase inhibitors for the management of treatment-experienced and treatment-naive HIV-infected patients.

Learning Objectives

Upon completion of this activity, participants should be able to:

Recount data from clinical studies of the use of the integrase inhibitors raltegravir and elvitegravir
Discuss the role of integrase inhibitors in the management of treatment-experienced patients
Identify management strategies for antiretroviral-experienced patients who experience virologic failure

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.